Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)
ID: 351449Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Public and State Controlled Institutions of Higher Education

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351449

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-078.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)" aimed at supporting breeding colonies of specific pathogen-free (SPF) macaques for research related to Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS). This initiative seeks to ensure the availability of SPF macaques, which are crucial for maintaining experimental integrity and personnel safety in HIV/AIDS research, by providing funding for colony maintenance, animal allocation to researchers, and ongoing viral testing to uphold SPF status. The grants will prioritize NIH-funded studies while ensuring that at least 50% of the animals are accessible to researchers outside the awarding institution, thereby fostering broader research applications. Interested applicants must submit their proposals by January 25, 2024, and can find additional information and contact details at grantsinfo@nih.gov or through the NIH grants website.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-078-Full-Announcement.html
    PAR-24-078.html
    The Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), has announced a funding opportunity titled "Limited Competition: Specific Pathogen Free Macaque Colonies" (U42 Clinical Trial Not Allowed) aimed at supporting breeding colonies of specific pathogen-free (SPF) macaques for HIV/AIDS research. This initiative seeks to uphold the availability of these critical models that are free of specific viruses, ensuring experimental integrity and personnel safety. This reissued funding opportunity (PAR-24-078) allows applications from organizations previously funded under related notices, emphasizing the significance of SPF macaques in studying HIV/AIDS and enhancing related biomedical research. The grants will support colony maintenance, allocation of animals to researchers (prioritizing NIH-funded studies), and ongoing viral testing to uphold SPF status. Key dates for application submissions range from April 2024 through January 2027, with proposals required to detail various aspects such as colony management, veterinary care, genetic typing, and sustainability plans. The review process will assess the scientific merit, innovation, and adequacy of proposed approaches. NIH aims to ensure that at least 50% of the animals are available to researchers outside the awarding institution to foster broader research applications.
    Similar Opportunities
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models," aimed at supporting preclinical research on HIV/AIDS conducted by early-stage investigators with at least two years of postdoctoral experience. This funding initiative encourages innovative research approaches utilizing NHP models to develop next-generation therapies and strategies for HIV cure, aligning with the NIH Strategic Plan priorities for HIV research. Eligible applicants can request up to $200,000 in direct costs annually, with a total budget cap of $400,000 over two years, and must adhere to specific application procedures. The application deadline is September 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Limited Competition: National Primate Research Centers (P51), aimed at supporting basic and translational research utilizing nonhuman primates (NHPs). This grant is specifically designed for existing National Primate Research Centers (NPRCs) to provide essential resources, expertise, and animal models crucial for advancing understanding of human biology in both normal and diseased states. The NPRCs play a vital role in biomedical research by ensuring rigorous study designs, facilitating pilot research projects, and promoting ethical treatment of research animals. Interested applicants must submit their proposals by January 25, 2024, with a maximum project period of five years, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-126.html.
    HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01), a federal grant opportunity aimed at supporting early-stage investigators in the field of HIV/AIDS translational studies. This program is designed for individuals within ten years of completing their terminal professional degree or residency, providing three years of mentored research support focused on utilizing NHPs as preclinical models to advance understanding and treatment of HIV/AIDS. Successful applicants must hold a full-time appointment at an institution with NHP facilities and commit at least 75% of their professional effort to the program, with funding of up to $100,000 annually for salary and research expenses. Interested applicants should submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" aimed at supporting Early Stage Investigators (ESIs) in conducting innovative preclinical research on HIV/AIDS using NHP models. This grant initiative seeks to empower researchers who are within ten years of their terminal degree and have at least two years of postdoctoral experience, enabling them to explore new research directions that align with the NIH Strategic Plan for HIV and HIV-Related Research for FY 2021-2025. The funding provides a maximum of $400,000 over a two-year period, with applications due by September 7, 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a funding opportunity for research focused on developing cellular models of HIV pathogenesis. This initiative aims to enhance understanding of HIV interactions with human tissues by utilizing innovative three-dimensional models, such as organoids and microphysiological systems, to investigate mechanisms of viral persistence and associated co-occurring conditions. The funding opportunity allows for a budget of up to $500,000 annually, with a total commitment of $3 million for the fiscal year 2026, and applications are due by March 20, 2025. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-021.html.
    Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Animal and Biological Material Resource Centers" (P40) aimed at supporting specialized colonies of laboratory animals and related resources to enhance scientific rigor and reproducibility in biomedical research. This funding initiative encourages applicants to propose centers that not only continue existing resources but also develop new ones based on the needs of the biomedical research community, providing unique animal models, informatics tools, and biological materials applicable across multiple NIH Institutes. The total funding commitment is anticipated to be $1.3 million over three years, with at least two grants awarded annually, and interested applicants must adhere to strict application guidelines, with submissions accepted until January 28, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)" aimed at researching the mechanisms of T-cell involvement in HIV-related central nervous system (CNS) issues. This initiative seeks to develop therapeutic strategies that address T-cell neuro-invasion and HIV-associated neuroinflammation, with a focus on innovative and multidisciplinary approaches utilizing advanced technologies. Approximately $5.5 million is available for this research, with applications opening on February 17, 2025, and a submission deadline of March 18, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.